New wavy lines, a sudden blur, or a blank spot in your central vision need same-day care. Call an eye doctor or go to the emergency department.

Hazleton Eye Specialists · Office 570-453-2020 · Fax 570-453-1020

Macular Degeneration Health

Referring providers: Refer a patient or ask a question · Same-day: 570-453-2020

Book an exam

Home Evidence References

References

Prepared for review by Dr. James Deom, OD, MPH, FAAO, FSLS, Chief of Eye Care Services, Hazleton Eye Specialists

Same-day care

New wavy lines, a sudden blur, or a blank spot in your central vision need same-day care.

Call an eye doctor or go to the emergency department the same day.

Call the office 570-453-2020Find an eye doctor 5 officesBook an exam Pick your office

This list is the working bibliography for v1. Retrieval dates are America/New_York. A longer, identically sourced list also lives at /workspace/amd-site/references.md.

Patient education

  1. National Eye Institute. Age-Related Macular Degeneration (AMD). Last updated June 22, 2021. Retrieved November 15, 2026. (The treatment section on this page predates the Valeda authorization and some later dry-AMD medicines; we do not present its “no treatment” sentences as current 2026 fact.)
  2. National Eye Institute. The latest on AMD. Retrieved November 15, 2026.
  3. American Academy of Ophthalmology. Understanding Macular Degeneration. Retrieved November 15, 2026. (Retrieved page describes dry vs wet AMD, AREDS2, and geographic-atrophy injections; it does not describe Valeda.)

FDA

  1. U.S. Food and Drug Administration. Device Classification Under Section 513(f)(2) (De Novo): DEN230083, Valeda Light Delivery System, LumiThera, Inc.. Decision date November 4, 2024.
  2. U.S. Food and Drug Administration. De Novo classification request for Valeda Light Delivery System (DEN230083) — decision summary. Retrieved November 15, 2026.
  3. U.S. Food and Drug Administration. FDA Roundup: November 5, 2024.

LIGHTSITE III

  1. Boyer D, Hu A, Warrow D, Xavier S, Gonzalez V, Lad E, Rosen RB, Do D, Schneiderman T, Ho A, Munk MR, Jaffe G. LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System. Retina. 2024;44(3):487–497. doi:10.1097/IAE.0000000000003980. PubMed 37972955.
  2. Jaffe GJ, Boyer D, Hu A, Warrow D, Xavier S, Gonzalez V, Lad E, Rosen RB, Do DV, Schneiderman T, Ho AC, Munk MR. Long-term efficacy and safety of photobiomodulation in dry age-related macular degeneration (LIGHTSITE III: 24-month analysis). Retina. 2026;46(5):783–795. doi:10.1097/IAE.0000000000004822. PubMed 41791029.

Practice pages (used only for what the practice states about its services)

  1. Hazleton Eye Specialists. Valeda Dry AMD Treatment. Retrieved November 15, 2026.
  2. Deom J. How Photobiomodulation Is Changing the Game in Macular Degeneration. drkislan.com. Posted June 6, 2025 (page also showed an April 16, 2026 stamp). Retrieved November 15, 2026. (“Among the first in Pennsylvania” is unverified; omitted from body copy pending confirmation.)
  3. Our Locations, James Deom, OD, MPH, FAAO, FSLS, Get to Know Us.

Medical disclaimer. This page is for general education only. It is not medical advice and does not replace an examination or a conversation with your own doctors. Do not start, stop, or change any medicine or treatment without talking to the clinician who cares for you. If you notice new wavy lines, a sudden blur, or a blank spot in your central vision, seek same-day care from an eye doctor or an emergency department.